Aveo-Astellas kidney cancer drug is not recommended by FDA advisers

05/3/2013 | Yahoo

An FDA advisory panel voted 13-1 against recommending approval of Aveo Pharmaceuticals and Astellas Pharma's tivozanib as treatment for kidney cancer, citing inconsistent data from a clinical trial. The panel said another trial would be needed. Though disappointed with the decision, Aveo and Astellas said they would consult with the agency to address the advisers' concerns.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC